Discovering the mechanism of action of a novel immunotherapy, Cat-SPIRE, using a network analysis

Allergic rhinitis is an inflammatory condition of the nasal passages induced after allergen exposure in sensitized individuals. Approximately 20-25% of Canadians suffer from allergic rhinitis, with cat allergy affecting up to 15% of people with allergic rhinitis and/or asthma. Although existing immunotherapies have some effectiveness, these have safety problems and require long-term treatment. A novel immunotherapy, Cat-Synthetic Peptide Immuno-Regulatory Epitopes (Cat-SPIRE), composed of seven synthetic molecules related to cat allergen, acts on allergen-specific immune cells to induce subsequent clinical tolerance to cat allergen with reduced side effects and a shorter treatment time. Its specific mechanism is not yet fully understood. Young Woong Kim will participate in a study to discover the mechanism using blood samples and clinical data obtained from research  participants who have undertaken Cat-SPIRE clinical trials at Adiga Life Sciences, Inc. The investigation of the effects of Cat-SPIRE will allow us to find significant gene expression signatures for diagnosis and effectiveness of the treatments.

Faculty Supervisor:

Scott Tebbutt


Young Woong Kim


Adiga Life Science Inc.




Life sciences


University of British Columbia



Current openings

Find the perfect opportunity to put your academic skills and knowledge into practice!

Find Projects